• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.140 -0.010 (-0.16%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
December 09, 2025
New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
November 25, 2025
Actionable offering helps enable earlier, more personalized breast cancer interventions 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
November 11, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
November 10, 2025
100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
November 06, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
November 03, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
October 31, 2025
Faster initial remission and response, persistent benefit over six months 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
October 27, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
October 14, 2025
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV
October 08, 2025
From D S Simon
Via GlobeNewswire
News headline image
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
September 23, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
September 04, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
September 03, 2025
Results published in the Journal of Clinical Psychopharmacology 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
August 27, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
ANGLE Announces Collaboration with Myriad Genetics
August 20, 2025
Via ACCESS Newswire
News headline image
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
August 18, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results
August 13, 2025
Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
August 05, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces New $200 Million Credit Facility
July 31, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025
July 29, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Earns 2025 Great Place To Work Certification™
July 15, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
June 03, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types
June 02, 2025
MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable via... 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
May 27, 2025
Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
May 14, 2025
Correction: Time of BofA Conference 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
May 08, 2025
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
May 08, 2025
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
May 07, 2025
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
May 07, 2025
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
May 06, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap